Jyoti Nangalia | Cancer Research UK Clinician Scientist

Nangalia, Jyoti

Jyoti is a CRUK Clinician Scientist and Consultant Haematologist. She utilises sequencing technologies to help understand why blood cancers originate and evolve, and how this relates to normal development and ageing.

Publications

  • Clonal approaches to understanding the impact of mutations on hematologic disease development.

    Nangalia J, Mitchell E and Green AR

    Blood 2019;133;13;1436-1445

  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

    Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N et al.

    The New England journal of medicine 2018;379;15;1416-1430

  • Myeloproliferative neoplasms: from origins to outcomes.

    Nangalia J and Green AR

    Blood 2017;130;23;2475-2483

  • Pathogenesis of Myeloproliferative Disorders.

    Nangalia J, Grinfeld J and Green AR

    Annual review of pathology 2016;11;101-26

  • DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

    Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J et al.

    Haematologica 2015;100;11;e438-42

  • Effect of mutation order on myeloproliferative neoplasms.

    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC et al.

    The New England journal of medicine 2015;372;7;601-612

  • MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

    Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A et al.

    Leukemia 2015;29;2;494-7

  • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G et al.

    The New England journal of medicine 2013;369;25;2391-2405

  • Clonal approaches to understanding the impact of mutations on hematologic disease development.

    Nangalia J, Mitchell E and Green AR

    Blood 2019;133;13;1436-1445

  • A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

    McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F et al.

    British journal of haematology 2019;184;2;161-175

  • A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

    McMullin MF, Harrison CN, Ali S, Cargo C, Chen F et al.

    British journal of haematology 2018

  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

    Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N et al.

    The New England journal of medicine 2018;379;15;1416-1430

  • Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

    Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018;JCO2018788414

  • Myeloproliferative neoplasms: from origins to outcomes.

    Nangalia J and Green AR

    Blood 2017;130;23;2475-2483

  • Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

    Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A et al.

    The Lancet. Haematology 2017;4;5;e225-e236

  • Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

    Grinfeld J, Nangalia J and Green AR

    Haematologica 2017;102;1;7-17

  • Pathogenesis of Myeloproliferative Disorders.

    Nangalia J, Grinfeld J and Green AR

    Annual review of pathology 2016;11;101-26

  • Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.

    Malherbe JA, Fuller KA, Arshad A, Nangalia J, Romeo G et al.

    Journal of clinical pathology 2016;69;2;155-63

  • RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

    Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL et al.

    Cell reports 2015;13;11;2345-52

  • DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

    Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J et al.

    Haematologica 2015;100;11;e438-42

  • Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

    Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR et al.

    Genome research 2015;25;6;814-24

  • Effect of mutation order on myeloproliferative neoplasms.

    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC et al.

    The New England journal of medicine 2015;372;7;601-612

  • MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.

    Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A et al.

    Leukemia 2015;29;2;494-7

  • Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.

    Jones AV, Ward D, Lyon M, Leung W, Callaway A et al.

    Leukemia research 2015;39;1;82-7

  • Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

    Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K et al.

    Nature communications 2015;6;6691

  • The evolving genomic landscape of myeloproliferative neoplasms.

    Nangalia J and Green TR

    Hematology. American Society of Hematology. Education Program 2014;2014;1;287-96

  • Nongenetic stochastic expansion of JAK2V617F-homozygous subclones in polycythemia vera?

    Godfrey AL, Nangalia J, Baxter EJ, Massie CE, Kent DG et al.

    Blood 2014;124;22;3332-4

  • JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

    Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL et al.

    Proceedings of the National Academy of Sciences of the United States of America 2014;111;42;15190-5

  • Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer.

    Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S et al.

    eLife 2014;3

  • JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

    Li J, Kent DG, Godfrey AL, Manning H, Nangalia J et al.

    Blood 2014;123;20;3139-51

  • CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.

    Guglielmelli P, Nangalia J, Green AR and Vannucchi AM

    American journal of hematology 2014;89;5;453-6

  • BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms.

    Wyspiańska BS, Bannister AJ, Barbieri I, Nangalia J, Godfrey A et al.

    Leukemia 2014;28;1;88-97

  • Inactivating CUX1 mutations promote tumorigenesis.

    Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C et al.

    Nature genetics 2014;46;1;33-8

  • Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

    Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G et al.

    The New England journal of medicine 2013;369;25;2391-2405

  • Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions.

    Aziz A, Baxter EJ, Edwards C, Cheong CY, Ito M et al.

    The Journal of clinical investigation 2013;123;5;2169-82

  • Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support.

    Nangalia J, Smith H and Wimperis JZ

    Leukemia & lymphoma 2008;49;8;1530-6

  • Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

    Li W, Adams TE, Nangalia J, Esmon CT and Huntington JA

    Proceedings of the National Academy of Sciences of the United States of America 2008;105;12;4661-6

Nangalia, Jyoti
Jyoti's Timeline
2016

Advanced Research Grant | European Haematology Association

Cancer Research UK Clinician Scientist Fellowship

2015

PhD awarded | University of Cambridge

Completion of Specialist Training | Haematology

Translational Research Training in Haematology Fellow | ASH-EHA | Class of 2015

2014

Johnstone & Florence Stoney Scholarship | British Federation of Women Graduates

2011

PhD commenced | University of Cambridge

2010

Member of the Royal College of Pathologists

2007

Academic Clinical Fellow | Haematology | East of England

2004

MB BChir | University of Cambridge